Drug interactions
Encorafenib + Tolterodine
Severity: Moderate
Encorafenib and Tolterodine: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib has mixed inhibitory and inducing effects on CYP3A4, so tolterodine exposure may rise or fall unpredictably. Tolterodine is cleared by CYP2D6 and CYP3A4, so the effect is modest in most patients. Changes may alter anticholinergic adverse effects or efficacy.
What this interaction means in plain words
Encorafenib and Tolterodine can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Encorafenib belongs to Oncology; Tolterodine belongs to Genitourinary.
Why it happens
Mixed CYP3A4 inhibition and induction by encorafenib altering tolterodine metabolism.
What to do
Monitor for anticholinergic adverse effects (dry mouth, retention, QT effects) and for loss of efficacy. Adjust tolterodine dose according to response and tolerability.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Tolterodine, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Tolterodine
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Tolterodine?
MediHelp rates the interaction as moderate. Encorafenib and Tolterodine can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Encorafenib has mixed inhibitory and inducing effects on CYP3A4, so tolterodine exposure may rise or fall unpredictably. Tolterodine is cleared by CYP2D6 and CYP3A4, so the effect is modest in most patients. Changes may alter anticholinergic adverse effects or efficacy.
How serious is the interaction between Encorafenib and Tolterodine?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for anticholinergic adverse effects (dry mouth, retention, QT effects) and for loss of efficacy. Adjust tolterodine dose according to response and tolerability.
What other medicines interact with Tolterodine?
MediHelp also lists interactions of Tolterodine with, for example, Clarithromycin, Clozapine, Cobicistat. The full list is on the Tolterodine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
